Notice of Proposed Sale · 144

Annexon, Inc.

ANNXNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Aug 13, 2026Accepted Aug 13, 2026, 3:34 PM EDTFiling CIK 1208907Accession 0001959173-26-005993

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Annexon, Inc.
Issuer CIK: 0001528115
SEC file number: 001-39402
Phone: (650) 822-5500
Person for whose account securities are to be sold: WIGGANS THOMAS G
Relationships to issuer: Former Director
Street: 1400 SIERRA POINT PARKWAY
Street (continued): BLDG C, SUITE 200
City: BRISBANE
State / country code: CA
Postal code: 94005

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	2,000	10,596.00	189,579,134	08/13/2026	NASDAQ	Fidelity Brokerage Services LLC

Broker / market maker — proposed row 1, entry 1

Name: Fidelity Brokerage Services LLC
Street: 900 Salem Street
City: Smithfield
State / country code: RI
Postal code: 02917

Acquisition of securities to be sold

Acquisition of securities to be sold · 1 reported row
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	08/13/2026	Stock Option Exercise	Issuer	2,000	N	08/13/2026	Cash

Sales reported in the preceding three months

Sales reported in the preceding three months · 2 reported rows
Seller	Security	Sale date	Amount sold	Gross proceeds
Thomas Wiggans	Common	07/14/2026	1,000	5,605.00
Thomas Wiggans	Common	07/15/2026	2,000	12,630.00

Seller — prior-sale row 1, entry 1

Name: Thomas Wiggans
Street: 1400 Sierra Point Parkway
Street (continued): Bldg C, Suite 200
City: Brisbane
State / country code: CA
Postal code: 94005

Seller — prior-sale row 2, entry 1

Name: Thomas Wiggans
Street: 1400 Sierra Point Parkway
Street (continued): Bldg C, Suite 200
City: Brisbane
State / country code: CA
Postal code: 94005

Prior-sale reporting

Nothing to report for the preceding three months: N

Notice signature

Notice date: 08/13/2026
Signed: /s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Thomas Wiggans.

Company context

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Current securities

ANNXNASDAQ · EQUITY · Current

Get the free weekly BCS email.